Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial
Satisfactory treatment is often lacking for spasticity, a highly prevalent motor disorder in patients with spinal cord injury (SCI). Low concentrations of riluzole potently reduce the persistent sodium current, the post-SCI increase in which contributes to spasticity. The repurposing of this drug ma...
Gespeichert in:
| Veröffentlicht in: | PloS one 2023-01, Vol.18 (1), p.e0276892 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | e0276892 |
| container_title | PloS one |
| container_volume | 18 |
| creator | Cotinat, Maëva Boquet, Isabelle Ursino, Moreno Brocard, Cécile Jouve, Elisabeth Alberti, Corinne Bensoussan, Laurent Viton, Jean-Michel Brocard, Frédéric Blin, Olivier |
| description | Satisfactory treatment is often lacking for spasticity, a highly prevalent motor disorder in patients with spinal cord injury (SCI). Low concentrations of riluzole potently reduce the persistent sodium current, the post-SCI increase in which contributes to spasticity. The repurposing of this drug may therefore constitute a useful potential therapeutic option for relieving SCI patients suffering from chronic traumatic spasticity.
RILUSCI is a phase 1b-2b trial designed to assess whether riluzole is a safe and biologically effective means of managing spasticity in adult patients with traumatic chronic SCI.
In this multicenter double-blind trial, adults (aged 18-65 years) suffering from spasticity after SCI (target enrollment: 90 participants) will be randomly assigned to be given either a placebo or a recommended daily oral dose of riluzole for two weeks. The latter dose will be previously determined in phase 1b of the study by performing double-blind dose-finding tests using a Bayesian continuous reassessment method. The primary endpoint of the trial will be an improvement in the Modified Ashworth Score (MAS) or the Numerical Rating Score (NRS) quantifying spasticity. The secondary outcomes will be based on the safety and pharmacokinetics of riluzole as well as its impact on muscle spasms, pain, bladder dysfunction and quality of life. Analyses will be performed before, during and after the treatment and the placebo-controlled period.
To the best of our knowledge, this clinical trial will be the first to document the safety and efficacy of riluzole as a means of reducing spasticity in patients with chronic SCI.
The clinical trial, which is already in progress, was registered on the ClinicalTrials.gov website on August 9, 2016 under the registration number NCT02859792.
Assistance Publique-Hôpitaux de Marseille. |
| doi_str_mv | 10.1371/journal.pone.0276892 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2767424732</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A733942761</galeid><doaj_id>oai_doaj_org_article_1371cf8d1b024adfa678858fc0729a1a</doaj_id><sourcerecordid>A733942761</sourcerecordid><originalsourceid>FETCH-LOGICAL-c687t-a879af4525b7001602ff93d536053e147256dbdf30b2e0c8358217d809581f4d3</originalsourceid><addsrcrecordid>eNqNk9FqFDEUhgdRbK2-gWhAELzYNpPMJBkvhKWoXVgotNbbkEkyO1mykzHJVLev5Qua6U7LriB4NeHkO_8_5w8ny17n8DTHND9bu8F3wp72rtOnEFHCKvQkO84rjGYEQfx073yUvQhhDWGJGSHPsyNMCEGMVMfZ7ytjhztnNWicB9FrEU23AqEXIRpp4haYDvSpqLsYwE8TWyBb7zojEyyGTbqRiTbpT4B0XiV8PfjtR3AdB7UFvXfRSWdHldhq0LciaGDqM2NqIJToo7nVYDPYJJMctAdedMptzJ1WSa-L3lmbjleL5c31-SJ5GmFfZs8aYYN-NX1Pspsvn7-dX8yWl18X5_PlTBJG40wwWommKFFZUwhzAlHTVFiVmKQcdF5QVBJVqwbDGmkoGS4ZyqlisCpZ3hQKn2Rvd7q9dYFPeQeeoqYFKihGiVjsCOXEmvfebITfcicMvy84v-LCp9Gs5uObyYapvIaoEKoRhDJWskZCiiqRi6T1aXIb6o1WYxxe2APRw5vOtHzlbnmVZBjMk8CHnUD7V9vFfMnHGiwgo5gUtyP7bjLz7segQ_zHeBO1EmkC0zUuGcuNCZLPKcZVkdg934kan03_iisxhMAX11f_z15-P2Tf77GtFja2wdkhGteFQ7DYgdK7ELxuHqfP4X3uD8PxcVf4tCup7c1-4I9ND8uB_wAQRBHm</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2767424732</pqid></control><display><type>article</type><title>Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Cotinat, Maëva ; Boquet, Isabelle ; Ursino, Moreno ; Brocard, Cécile ; Jouve, Elisabeth ; Alberti, Corinne ; Bensoussan, Laurent ; Viton, Jean-Michel ; Brocard, Frédéric ; Blin, Olivier</creator><creatorcontrib>Cotinat, Maëva ; Boquet, Isabelle ; Ursino, Moreno ; Brocard, Cécile ; Jouve, Elisabeth ; Alberti, Corinne ; Bensoussan, Laurent ; Viton, Jean-Michel ; Brocard, Frédéric ; Blin, Olivier</creatorcontrib><description>Satisfactory treatment is often lacking for spasticity, a highly prevalent motor disorder in patients with spinal cord injury (SCI). Low concentrations of riluzole potently reduce the persistent sodium current, the post-SCI increase in which contributes to spasticity. The repurposing of this drug may therefore constitute a useful potential therapeutic option for relieving SCI patients suffering from chronic traumatic spasticity.
RILUSCI is a phase 1b-2b trial designed to assess whether riluzole is a safe and biologically effective means of managing spasticity in adult patients with traumatic chronic SCI.
In this multicenter double-blind trial, adults (aged 18-65 years) suffering from spasticity after SCI (target enrollment: 90 participants) will be randomly assigned to be given either a placebo or a recommended daily oral dose of riluzole for two weeks. The latter dose will be previously determined in phase 1b of the study by performing double-blind dose-finding tests using a Bayesian continuous reassessment method. The primary endpoint of the trial will be an improvement in the Modified Ashworth Score (MAS) or the Numerical Rating Score (NRS) quantifying spasticity. The secondary outcomes will be based on the safety and pharmacokinetics of riluzole as well as its impact on muscle spasms, pain, bladder dysfunction and quality of life. Analyses will be performed before, during and after the treatment and the placebo-controlled period.
To the best of our knowledge, this clinical trial will be the first to document the safety and efficacy of riluzole as a means of reducing spasticity in patients with chronic SCI.
The clinical trial, which is already in progress, was registered on the ClinicalTrials.gov website on August 9, 2016 under the registration number NCT02859792.
Assistance Publique-Hôpitaux de Marseille.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0276892</identifier><identifier>PMID: 36662869</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Amyotrophic lateral sclerosis ; Bayes Theorem ; Bayesian analysis ; Biological effects ; Care and treatment ; Clinical trials ; Clinical Trials, Phase I as Topic ; Double-Blind Method ; Drug dosages ; Drug withdrawal ; Health risks ; Humans ; Injury prevention ; Life Sciences ; Low concentrations ; Medication ; Medicine and Health Sciences ; Multicenter Studies as Topic ; Muscle pain ; Muscle Spasticity - drug therapy ; Muscle Spasticity - etiology ; Muscles ; Pain ; Patient outcomes ; Patients ; People and Places ; Pharmaceutical sciences ; Pharmacokinetics ; Placebos ; Quality of Life ; Randomized Controlled Trials as Topic ; Rehabilitation ; Research and Analysis Methods ; Riluzole - therapeutic use ; Safety ; Sodium ; Spasms ; Spasticity ; Spinal Cord Injuries ; Study Protocol ; Treatment Outcome ; Websites</subject><ispartof>PloS one, 2023-01, Vol.18 (1), p.e0276892</ispartof><rights>Copyright: © 2023 Cotinat et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</rights><rights>COPYRIGHT 2023 Public Library of Science</rights><rights>2023 Cotinat et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><rights>2023 Cotinat et al 2023 Cotinat et al</rights><rights>2023 Cotinat et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c687t-a879af4525b7001602ff93d536053e147256dbdf30b2e0c8358217d809581f4d3</citedby><cites>FETCH-LOGICAL-c687t-a879af4525b7001602ff93d536053e147256dbdf30b2e0c8358217d809581f4d3</cites><orcidid>0000-0002-2028-5846 ; 0000-0002-2500-1224 ; 0000-0001-9444-9586</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858801/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858801/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79569,79570</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36662869$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04087364$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Cotinat, Maëva</creatorcontrib><creatorcontrib>Boquet, Isabelle</creatorcontrib><creatorcontrib>Ursino, Moreno</creatorcontrib><creatorcontrib>Brocard, Cécile</creatorcontrib><creatorcontrib>Jouve, Elisabeth</creatorcontrib><creatorcontrib>Alberti, Corinne</creatorcontrib><creatorcontrib>Bensoussan, Laurent</creatorcontrib><creatorcontrib>Viton, Jean-Michel</creatorcontrib><creatorcontrib>Brocard, Frédéric</creatorcontrib><creatorcontrib>Blin, Olivier</creatorcontrib><title>Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Satisfactory treatment is often lacking for spasticity, a highly prevalent motor disorder in patients with spinal cord injury (SCI). Low concentrations of riluzole potently reduce the persistent sodium current, the post-SCI increase in which contributes to spasticity. The repurposing of this drug may therefore constitute a useful potential therapeutic option for relieving SCI patients suffering from chronic traumatic spasticity.
RILUSCI is a phase 1b-2b trial designed to assess whether riluzole is a safe and biologically effective means of managing spasticity in adult patients with traumatic chronic SCI.
In this multicenter double-blind trial, adults (aged 18-65 years) suffering from spasticity after SCI (target enrollment: 90 participants) will be randomly assigned to be given either a placebo or a recommended daily oral dose of riluzole for two weeks. The latter dose will be previously determined in phase 1b of the study by performing double-blind dose-finding tests using a Bayesian continuous reassessment method. The primary endpoint of the trial will be an improvement in the Modified Ashworth Score (MAS) or the Numerical Rating Score (NRS) quantifying spasticity. The secondary outcomes will be based on the safety and pharmacokinetics of riluzole as well as its impact on muscle spasms, pain, bladder dysfunction and quality of life. Analyses will be performed before, during and after the treatment and the placebo-controlled period.
To the best of our knowledge, this clinical trial will be the first to document the safety and efficacy of riluzole as a means of reducing spasticity in patients with chronic SCI.
The clinical trial, which is already in progress, was registered on the ClinicalTrials.gov website on August 9, 2016 under the registration number NCT02859792.
Assistance Publique-Hôpitaux de Marseille.</description><subject>Adult</subject><subject>Amyotrophic lateral sclerosis</subject><subject>Bayes Theorem</subject><subject>Bayesian analysis</subject><subject>Biological effects</subject><subject>Care and treatment</subject><subject>Clinical trials</subject><subject>Clinical Trials, Phase I as Topic</subject><subject>Double-Blind Method</subject><subject>Drug dosages</subject><subject>Drug withdrawal</subject><subject>Health risks</subject><subject>Humans</subject><subject>Injury prevention</subject><subject>Life Sciences</subject><subject>Low concentrations</subject><subject>Medication</subject><subject>Medicine and Health Sciences</subject><subject>Multicenter Studies as Topic</subject><subject>Muscle pain</subject><subject>Muscle Spasticity - drug therapy</subject><subject>Muscle Spasticity - etiology</subject><subject>Muscles</subject><subject>Pain</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>People and Places</subject><subject>Pharmaceutical sciences</subject><subject>Pharmacokinetics</subject><subject>Placebos</subject><subject>Quality of Life</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Rehabilitation</subject><subject>Research and Analysis Methods</subject><subject>Riluzole - therapeutic use</subject><subject>Safety</subject><subject>Sodium</subject><subject>Spasms</subject><subject>Spasticity</subject><subject>Spinal Cord Injuries</subject><subject>Study Protocol</subject><subject>Treatment Outcome</subject><subject>Websites</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9FqFDEUhgdRbK2-gWhAELzYNpPMJBkvhKWoXVgotNbbkEkyO1mykzHJVLev5Qua6U7LriB4NeHkO_8_5w8ny17n8DTHND9bu8F3wp72rtOnEFHCKvQkO84rjGYEQfx073yUvQhhDWGJGSHPsyNMCEGMVMfZ7ytjhztnNWicB9FrEU23AqEXIRpp4haYDvSpqLsYwE8TWyBb7zojEyyGTbqRiTbpT4B0XiV8PfjtR3AdB7UFvXfRSWdHldhq0LciaGDqM2NqIJToo7nVYDPYJJMctAdedMptzJ1WSa-L3lmbjleL5c31-SJ5GmFfZs8aYYN-NX1Pspsvn7-dX8yWl18X5_PlTBJG40wwWommKFFZUwhzAlHTVFiVmKQcdF5QVBJVqwbDGmkoGS4ZyqlisCpZ3hQKn2Rvd7q9dYFPeQeeoqYFKihGiVjsCOXEmvfebITfcicMvy84v-LCp9Gs5uObyYapvIaoEKoRhDJWskZCiiqRi6T1aXIb6o1WYxxe2APRw5vOtHzlbnmVZBjMk8CHnUD7V9vFfMnHGiwgo5gUtyP7bjLz7segQ_zHeBO1EmkC0zUuGcuNCZLPKcZVkdg934kan03_iisxhMAX11f_z15-P2Tf77GtFja2wdkhGteFQ7DYgdK7ELxuHqfP4X3uD8PxcVf4tCup7c1-4I9ND8uB_wAQRBHm</recordid><startdate>20230120</startdate><enddate>20230120</enddate><creator>Cotinat, Maëva</creator><creator>Boquet, Isabelle</creator><creator>Ursino, Moreno</creator><creator>Brocard, Cécile</creator><creator>Jouve, Elisabeth</creator><creator>Alberti, Corinne</creator><creator>Bensoussan, Laurent</creator><creator>Viton, Jean-Michel</creator><creator>Brocard, Frédéric</creator><creator>Blin, Olivier</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-2028-5846</orcidid><orcidid>https://orcid.org/0000-0002-2500-1224</orcidid><orcidid>https://orcid.org/0000-0001-9444-9586</orcidid></search><sort><creationdate>20230120</creationdate><title>Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial</title><author>Cotinat, Maëva ; Boquet, Isabelle ; Ursino, Moreno ; Brocard, Cécile ; Jouve, Elisabeth ; Alberti, Corinne ; Bensoussan, Laurent ; Viton, Jean-Michel ; Brocard, Frédéric ; Blin, Olivier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c687t-a879af4525b7001602ff93d536053e147256dbdf30b2e0c8358217d809581f4d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Amyotrophic lateral sclerosis</topic><topic>Bayes Theorem</topic><topic>Bayesian analysis</topic><topic>Biological effects</topic><topic>Care and treatment</topic><topic>Clinical trials</topic><topic>Clinical Trials, Phase I as Topic</topic><topic>Double-Blind Method</topic><topic>Drug dosages</topic><topic>Drug withdrawal</topic><topic>Health risks</topic><topic>Humans</topic><topic>Injury prevention</topic><topic>Life Sciences</topic><topic>Low concentrations</topic><topic>Medication</topic><topic>Medicine and Health Sciences</topic><topic>Multicenter Studies as Topic</topic><topic>Muscle pain</topic><topic>Muscle Spasticity - drug therapy</topic><topic>Muscle Spasticity - etiology</topic><topic>Muscles</topic><topic>Pain</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>People and Places</topic><topic>Pharmaceutical sciences</topic><topic>Pharmacokinetics</topic><topic>Placebos</topic><topic>Quality of Life</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Rehabilitation</topic><topic>Research and Analysis Methods</topic><topic>Riluzole - therapeutic use</topic><topic>Safety</topic><topic>Sodium</topic><topic>Spasms</topic><topic>Spasticity</topic><topic>Spinal Cord Injuries</topic><topic>Study Protocol</topic><topic>Treatment Outcome</topic><topic>Websites</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cotinat, Maëva</creatorcontrib><creatorcontrib>Boquet, Isabelle</creatorcontrib><creatorcontrib>Ursino, Moreno</creatorcontrib><creatorcontrib>Brocard, Cécile</creatorcontrib><creatorcontrib>Jouve, Elisabeth</creatorcontrib><creatorcontrib>Alberti, Corinne</creatorcontrib><creatorcontrib>Bensoussan, Laurent</creatorcontrib><creatorcontrib>Viton, Jean-Michel</creatorcontrib><creatorcontrib>Brocard, Frédéric</creatorcontrib><creatorcontrib>Blin, Olivier</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cotinat, Maëva</au><au>Boquet, Isabelle</au><au>Ursino, Moreno</au><au>Brocard, Cécile</au><au>Jouve, Elisabeth</au><au>Alberti, Corinne</au><au>Bensoussan, Laurent</au><au>Viton, Jean-Michel</au><au>Brocard, Frédéric</au><au>Blin, Olivier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2023-01-20</date><risdate>2023</risdate><volume>18</volume><issue>1</issue><spage>e0276892</spage><pages>e0276892-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Satisfactory treatment is often lacking for spasticity, a highly prevalent motor disorder in patients with spinal cord injury (SCI). Low concentrations of riluzole potently reduce the persistent sodium current, the post-SCI increase in which contributes to spasticity. The repurposing of this drug may therefore constitute a useful potential therapeutic option for relieving SCI patients suffering from chronic traumatic spasticity.
RILUSCI is a phase 1b-2b trial designed to assess whether riluzole is a safe and biologically effective means of managing spasticity in adult patients with traumatic chronic SCI.
In this multicenter double-blind trial, adults (aged 18-65 years) suffering from spasticity after SCI (target enrollment: 90 participants) will be randomly assigned to be given either a placebo or a recommended daily oral dose of riluzole for two weeks. The latter dose will be previously determined in phase 1b of the study by performing double-blind dose-finding tests using a Bayesian continuous reassessment method. The primary endpoint of the trial will be an improvement in the Modified Ashworth Score (MAS) or the Numerical Rating Score (NRS) quantifying spasticity. The secondary outcomes will be based on the safety and pharmacokinetics of riluzole as well as its impact on muscle spasms, pain, bladder dysfunction and quality of life. Analyses will be performed before, during and after the treatment and the placebo-controlled period.
To the best of our knowledge, this clinical trial will be the first to document the safety and efficacy of riluzole as a means of reducing spasticity in patients with chronic SCI.
The clinical trial, which is already in progress, was registered on the ClinicalTrials.gov website on August 9, 2016 under the registration number NCT02859792.
Assistance Publique-Hôpitaux de Marseille.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>36662869</pmid><doi>10.1371/journal.pone.0276892</doi><tpages>e0276892</tpages><orcidid>https://orcid.org/0000-0002-2028-5846</orcidid><orcidid>https://orcid.org/0000-0002-2500-1224</orcidid><orcidid>https://orcid.org/0000-0001-9444-9586</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2023-01, Vol.18 (1), p.e0276892 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2767424732 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Adult Amyotrophic lateral sclerosis Bayes Theorem Bayesian analysis Biological effects Care and treatment Clinical trials Clinical Trials, Phase I as Topic Double-Blind Method Drug dosages Drug withdrawal Health risks Humans Injury prevention Life Sciences Low concentrations Medication Medicine and Health Sciences Multicenter Studies as Topic Muscle pain Muscle Spasticity - drug therapy Muscle Spasticity - etiology Muscles Pain Patient outcomes Patients People and Places Pharmaceutical sciences Pharmacokinetics Placebos Quality of Life Randomized Controlled Trials as Topic Rehabilitation Research and Analysis Methods Riluzole - therapeutic use Safety Sodium Spasms Spasticity Spinal Cord Injuries Study Protocol Treatment Outcome Websites |
| title | Riluzole for treating spasticity in patients with chronic traumatic spinal cord injury: Study protocol in the phase ib/iib adaptive multicenter randomized controlled RILUSCI trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T09%3A43%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Riluzole%20for%20treating%20spasticity%20in%20patients%20with%20chronic%20traumatic%20spinal%20cord%20injury:%20Study%20protocol%20in%20the%20phase%20ib/iib%20adaptive%20multicenter%20randomized%20controlled%20RILUSCI%20trial&rft.jtitle=PloS%20one&rft.au=Cotinat,%20Ma%C3%ABva&rft.date=2023-01-20&rft.volume=18&rft.issue=1&rft.spage=e0276892&rft.pages=e0276892-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0276892&rft_dat=%3Cgale_plos_%3EA733942761%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2767424732&rft_id=info:pmid/36662869&rft_galeid=A733942761&rft_doaj_id=oai_doaj_org_article_1371cf8d1b024adfa678858fc0729a1a&rfr_iscdi=true |